ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALIM Alimera Sciences Inc

3.48
0.00 (0.00%)
Pre Market
Last Updated: 12:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Alimera Sciences Inc NASDAQ:ALIM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.48 3.01 3.99 50 12:30:00

Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference

03/03/2017 3:05pm

GlobeNewswire Inc.


Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Alimera Sciences Charts.

Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 37th Annual Cowen Health Care Conference, to be held March 6-8, 2017 at The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Monday, March 6, 2017, at 4:40 PM Eastern Time.

A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimeraciences.com. A replay of the conference presentation will also be available.

About Alimera SciencesAlimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

Contact:
CG Capital
877.889.1972
investorrelations@cg.capital
cg.capital

1 Year Alimera Sciences Chart

1 Year Alimera Sciences Chart

1 Month Alimera Sciences Chart

1 Month Alimera Sciences Chart